Looking ahead: Israel sets up 2022 COVID-19 vaccine supply with Pfizer and Moderna

By Rachel Arthur contact

- Last updated on GMT

Pic:getty/peterschriebermedia
Pic:getty/peterschriebermedia

Related tags: Pfizer, Moderna, COVID-19 vaccine, israel

Israel has set up COVID-19 vaccine orders with Pfizer and Moderna this week: marking deals over the longer term for the two companies.

The Moderna deal is the company’s first firm agreement for 2022: and the deal includes the option for Israel to purchase the company’s variant-specific vaccines,​ subject to regulatory approval.

Meanwhile, Pfizer will also supply Israel with doses in 2022: while elsewhere the company is also in negotiations with the EU for a 1.8 billion mega order of COVID-19 vaccine doses​ for delivery through 2023.

Extending Israel's success story into 2022

With 55% of the population already fully vaccinated, Israel is a leader in COVID-19 vaccination and increasingly presented as a model of a successful vaccination campaign for the rest of the world.

The country started its vaccination campaign with the emergency use authorization of the Pfizer/BioNTech vaccine on December 6, 2020 (just a few days after the company’s first global authorization in the UK). Moderna’s vaccine was authorized on January 4.

This week’s COVID-19 vaccine deals will “ensure the continuation of Israel's ability to deal with the coronavirus in an optimal manner at least until the end of 2022,” ​said the government as it announced the Pfizer deal on Tuesday.

Details on the number of doses or the financial terms have not been disclosed.

Stéphane Bancel, Chief Executive Officer of Moderna, said: “This is an important moment for our company as the first firm order for 2022 supply and for the supply of our variant-specific booster vaccine candidates against COVID-19, currently being studied in human clinical trials. Recent preclinical results have shown that our variant-specific booster candidates were effective against COVID-19 variants of concerns, and we hope to continue to see positive results from the clinical studies.”

Related topics: Markets & Regulations, COVID-19

Related news

Show more

Follow us

Products

View more

Webinars